Neurocrine Biosciences (NBIX) EV to CFO (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EV to CFO for 17 consecutive years, with 122.68 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO rose 9.12% year-over-year to 122.68; the trailing twelve-month figure through Jun 2026 stood at 18.63 (down 7.83% YoY), and the FY2025 full-year result was 16.25, down 22.56% from the prior year.
• EV to CFO advanced to 122.68 in Q2 2026 per NBIX's latest filing, from 81.87 in the prior quarter.
• Across five years, EV to CFO topped out at 198.95 in Q2 2024 and bottomed at 204.65 in Q1 2022.
• Historically, EV to CFO has averaged 62.19 across 5 years, with a median of 69.83 in 2022.
• The sharpest annual moves came in 2022 and 2024: EV to CFO slumped 314.82% in 2022, then surged 334.31% in 2024.
• Over 5 years, EV to CFO stood at 73.63 in 2022, then surged by 31.58% to 96.88 in 2023, then tumbled by 46.83% to 51.51 in 2024, then slumped by 36.44% to 32.74 in 2025, then soared by 274.7% to 122.68 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 122.68, 81.87, and 32.74 for Q2 2026, Q1 2026, and Q4 2025 respectively.